Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer

Author:

Bahl A.1,Singh R.2,Wadhwa J.3,Gupta S.4,Ahmed M.5,Uppal P. N.6,Parikh Purvish M.7,Aggarwal S.8

Affiliation:

1. Deparment of Medical Oncology, Max Hospital, New Delhi

2. Department of Medical Oncology, Artemis Hospital, Gurugram

3. Department of Medical Oncology, Medanta Hospital, Gurugram

4. Department of Medical Oncology, Sarvodaya Hospital, New Delhi

5. Departmentt of Radiation Oncology, Jolly Grant Himalayan Institute, Dehradoon

6. Department of Surgical Oncology, Jaipur Golden Hospital, New Delhi

7. Department of Oncology, Shalby Cancer and Research Institute, Mumbai, Maharashtra

8. Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi

Abstract

AbstractOver-expression of HER2 is generally considered to be a negative prognostic feature because it accompanies an increase in breast cancer mortality. However, the development of agents that specifically target HER2 has improved the management of patients with these tumours. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at these practical consensus recommendations with regards to the use of these agents and the management of HER2 neu early breast cancer for the benefit of community oncologists.

Publisher

Georg Thieme Verlag KG

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3